4.7 Article

Intermittent Theta Burst Stimulation in Veterans with Mild Alcohol Use Disorder

期刊

JOURNAL OF AFFECTIVE DISORDERS
卷 293, 期 -, 页码 314-319

出版社

ELSEVIER
DOI: 10.1016/j.jad.2021.06.039

关键词

PTSD; depression; alcohol use; neurostimulation

资金

  1. VA RR&D Center for Neurorestoration and Neurotechnology, Department of Veterans Affairs [I01 RX002450, I01 HX002572]
  2. NIH [P20 GM130452]

向作者/读者索取更多资源

The study found that in PTSD patients, comorbid mild AUD does not affect the safety of iTBS treatment, and AUD patients showed a faster improvement rate in depression symptoms after receiving active stimulation.
Background: Alcohol use disorder (AUD) is highly comorbid with depression and posttraumatic stress disorder (PTSD) and can complicate their treatment. Transcranial magnetic stimulation is a promising treatment for these disorders, yet prior research often excluded AUD patients out of concern for safety or poorer outcomes. To this end, we revisited a prior study of intermittent theta burst stimulation (iTBS) for PTSD, to evaluate whether mild AUD impacted safety and clinical outcomes. Methods: Fifty veterans with PTSD (n=17, with comorbid AUD) received 10 days of sham-controlled iTBS, followed by 10 unblinded sessions. Stimulation was delivered at 80% of the motor threshold for 1800 pulses to the right dorsolateral prefrontal cortex. Safety, PTSD and depressive outcomes were evaluated with repeated measures analysis of variance, to examine the effects of time, treatment group and comorbid AUD. Results: iTBS was safe, although AUD patients reported more adverse events, regardless of whether they received active or sham stimulation. Regarding clinical outcomes, patients with AUD who received active stimulation demonstrated a greater rate of improvement in depression symptoms than those without comorbid AUD. The presence of AUD did not impact PTSD symptom change. Limitations: Limitations include a modest sample size and use of a categorical, rather than continuous, index of AUD diagnosis. Conclusion: While these results require replication, they indicate that iTBS is likely safe in patients with mild comorbid AUD. We propose that comorbid AUD should not preclude clinical use of iTBS, and that iTBS should be further investigated as a novel treatment option for AUD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据